组蛋白赖氨酸去甲基化酶在肿瘤中的作用

在肿瘤发生过程中,组蛋白赖氨酸去甲基化酶(LSD1)的表达失调是一个重要标志。LSD1能够于组蛋白H3的N端与H3K4me2/1和H3K9me2/1相互作用,并使其去甲基化,从而调控多种不同的生理过程。同时,LSD1表达水平变化还与多种基因如p53、DNMT1和EZH2等的表达水平相关联,在胚胎发育、细胞分化和肿瘤增殖转移过程中起重要作用。     

赖氨酸特异性组蛋白去甲基化酶1与白血病的研究进展

表观遗传学是后基因组时代兴起的一门新学科,它使人们认识到包括DNA甲基化、组蛋白修饰、染色质重塑及非编码RNA调控在内的修饰也可以记载遗传信息;并且许多表观遗传改变是可逆的,对表观遗传修饰和调控的研究已成为生命科学的热点和发展前沿。2004年发现的赖氨酸特异性组蛋白去甲基化酶1(LSD1)是第一个真正意义上的组蛋白赖氨酸去甲基化酶,使人们认识到组蛋白甲基化是一个动态的过程,通过组蛋白甲基转移酶和去甲基化酶的相互作用,动态地调控基因转录的激活和抑制等生物学过程。这重新定义了组蛋白甲基化,同时也为进一步深入研究组蛋白修饰提供了新的途径。我们在此简要介绍LSD1的结构与功能、LSD1与白血病的关系,LSD1在白血病的发生和发展中发挥重要作用,是一个潜在的治疗白血病的靶基因。     

表观遗传修饰与干细胞分化调控

干细胞具有自我更新和多种分化潜能的特性。干细胞向分化细胞的转变涉及到基因表达模式的改变,与自我更新有关的基因关闭．与细胞特化有关的基因激活。表观遗传调控机制,包括DNA甲基化、组蛋白修饰和微RNA（microRNA）介导的基因调控,在多个层面上控制发育过程中基因表达。近年研究表明,动态的表观遗传调控机制在干细胞自我更新和分化中起关键作用。     

赖氨酸特异性组蛋白去甲基化酶1作用机制及其生物学功能的研究进展

与其他化学修饰,如乙酰化、磷酸化、泛素化等相似,组蛋白赖氨酸甲基化是一个可以逆转的组蛋白修饰,是一个动态调节的过程。赖氨酸特异性组蛋白去甲基化酶1（lysine specific demethylase 1,LSD1）是一个黄素腺嘌呤二核苷酸（flavin adenine dinulcleotide,FAD）依赖性胺氧化酶,它能够特异性脱去H3K4和H3K9位点上的单甲基化和二甲基化的甲基基团。LSD1参与调控核受体介导的基因转录,并分别维持染色质的活性和非活性状态,被誉为细胞深处的基因＂开关＂。LSD1的功能失衡可引发多种重要生命现象的改变。主要综述LSD1的结构、作用机制及其在肿瘤发生、胚胎发育、体细胞重编程的调控、细胞分裂和造血等过程中生物学功能的研究新进展。     

组蛋白去甲基化酶LSD1及其生物学功能

赖氨酸特异性组蛋白去甲基化酶1(Lysine specific demethylase 1, LSD1) 的发现, 表明组蛋白的甲基化修饰是一个动态可调节的过程。结构分析显示, LSD1 是一个黄素腺嘌呤二核苷酸(Flavin adenine dinulcleotide, FAD) 依赖性胺氧化酶, 它能够特异性脱去单甲基化和二甲基化组蛋白H3第4位赖氨酸(H3K4) 和H3K9 位点上的甲基基团。功能研究显示, LSD1 定位于细胞核内, 调控着基因转录的激活和抑制, 被誉为细胞深处的基因“开关”, 在胚胎发育和肿瘤发生过程中起着重要的作用。文章主要综述了LSD1 的结构、作用机制及其调控作用研究的新进展。     

组蛋白去乙酰化酶抑制剂调控干细胞分化与体细胞重编程的研究进展

表观遗传调控,如组蛋白乙酰化修饰,是决定干细胞分化方向的重要机制。组蛋白去乙酰化酶抑制剂(HDACi)通过影响不同亚类的组蛋白去乙酰化酶(HDAC)活性,提高组蛋白乙酰化水平,调控基因表达,从而影响胚胎干细胞自我更新,以及沿神经元、心肌和造血等细胞谱系的定向分化。HDACi类小分子化合物在体细胞重编程中也有广泛的应用,可替代致癌因子c-Myc和Klf4,促进体细胞克隆。研究显示,HDACi的效应与药物剂量、细胞类型和细胞分化状态密切相关。本文主要阐述了HDACi在干细胞分化和体细胞重编程中的应用进展,并对所涉及的分子通路进行讨论,有助于揭示干细胞定向分化的关键分子机制,优化干细胞定向分化诱导策略,对干细胞诱导分化具有重要的理论和实用价值。     

组蛋白乙酰化对成体干细胞生物学性状的影响

成体干细胞（adult stem cells,ASCs）是指存在于一种已经分化组织中的未分化细胞,它们可以再生修复损伤的组织和器官,是组织工程和细胞治疗的理想细胞。但是ASCs在体外扩增过程中容易发生自主分化和衰老,影响其在临床的广泛应用。组蛋白乙酰化作为表观遗传调节的重要机制,参与细胞分化、衰老及凋亡等众多细胞活动的调控。该文就组蛋白乙酰化对成体干细胞生物学性状的影响进行综述。     

IL-3在造血干细胞增殖分化调控中的信号转导

IL-3又称多克隆集落刺激因子（Multi-CSF）,是造血干细胞增殖分化的正性调节因子。它通过与靶细胞表面的受体结合传递生长、分化信号,调控造血干细胞生存、增殖及向各系血细胞分化、成熟。本文就IL-3在造血干细胞增殖分化调控中的有关信号转导作一综述。     

干细胞中的DNA甲基化

DNA甲基化是表观遗传机制中一种重要的调控方式,它通过调控基因的表达影响一系列的生物学过程。干细胞作为具有自我更新、高度增殖和多向分化潜能的细胞群体,其分化和再生过程必然受到精确的表观调控。DNA甲基化在干细胞的维持、分化调控等方面都发挥着重要作用。现对胚胎干细胞、多能干细胞以及成体干细胞中DNA甲基化及羟甲基化的最新研究进展进行简要综述,回顾并展望DNA甲基化在干细胞中的潜在生物学功能及调控机制,同时为未来在临床诊断治疗及药物研发等方面提供一定的参考。     

胚胎干细胞分化过程中的表观遗传调控

作为一类既有自我更新能力,并具有多向分化潜能的细胞,胚胎干细胞具有非常重要的理论研究意义和临床应用前景。近期以胚胎干细胞为模型,研究有关干细胞分化的表观遗传调控已成为新的研究热点。本文就胚胎干细胞分化过程中DNA甲基化、组蛋白修饰、非编码RNA调控以及与胚胎干细胞分化密切相关的表观遗传学动态变化做一概述,对表观遗传学改变与胚胎干细胞分化关系的基础研究进行探讨。     

LSD1 Regulates Pluripotency of Embryonic Stem/Carcinoma Cells through Histone Deacetylase 1-Mediated Deacetylation of Histone H4 at Lysine 16

LSD1 is essential for the maintenance of pluripotency of embryonic stem (ES) or embryonic carcinoma/teratocarcinoma (EC) cells. We have previously developed novel LSD1 inhibitors that selectively inhibit ES/EC cells. However, the critical targets of LSD1 remain unclear. Here, we found that LSD1 interacts with histone deacetylase 1 (HDAC1) to regulate the proliferation of ES/EC cells through acetylation of histone H4 at lysine 16 (H4K16), which we show is a critical substrate of HDAC1. The LSD1 demethylase and HDAC1 deacetylase activities were both inactivated if one of them in the complex was chemically inhibited in ES/EC cells or in reconstituted protein complexes. Loss of HDAC1 phenocopied the selective growth-inhibitory effects and increased the levels of H3K4 methylation and H4K16 acetylation of LSD1 inactivation on ES/EC cells. Reduction of acetylated H4K16 by ablation of the acetyltransferase males absent on the first (MOF) is sufficient to rescue the growth inhibition induced by LSD1 inactivation. While LSD1 or HDAC1 inactivation caused the downregulation of Sox2 and Oct4 and induction of differentiation genes, such as FOXA2 or BMP2, depletion of MOF restored the levels of Sox2, Oct4, and FoxA2 in LSD1-deficient cells. Our studies reveal a novel mechanism by which LSD1 acts through the HDAC1- and MOF-mediated regulation of H4K16 acetylation to maintain the pluripotency of ES/EC cells.     

Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells

All-trans retinoic acid (ATRA) is a differentiation agent that revolutionized the treatment of acute promyelocytic leukemia. However, it has not been useful for other types of acute myeloid leukemia (AML). Here we explored the effect of SALL4, a stem cell factor, on ATRA-induced AML differentiation in both ATRA-sensitive and ATRA-resistant AML cells. Aberrant SALL4 expression has been found in nearly all human AML cases, whereas, in normal bone marrow and peripheral blood cells, its expression is only restricted to hematopoietic stem/progenitor cells. We reason that, in AMLs, SALL4 activation may prevent cell differentiation and/or protect self-renewal that is seen in normal hematopoietic stem/progenitor cells. Indeed, our studies show that ATRA-mediated myeloid differentiation can be largely blocked by exogenous expression of SALL4, whereas ATRA plus SALL4 knockdown causes significantly increased AML differentiation and cell death. Mechanistic studies indicate that SALL4 directly associates with retinoic acid receptor α and modulates ATRA target gene expression. SALL4 is shown to recruit lysine-specific histone demethylase 1 (LSD1) to target genes and alter the histone methylation status. Furthermore, coinhibition of LSD1 and SALL4 plus ATRA treatment exhibited the strongest anti-AML effect. These findings suggest that SALL4 plays an unfavorable role in ATRA-based regimes, highlighting an important aspect of leukemia therapy.     

MiR-137 knockdown promotes the osteogenic differentiation of human adipose-derived stem cells via the LSD1/BMP2/SMAD4 signaling network

MicroRNAs are a group of endogenous regulators that participate in several cellular physiological processes. However, the role of miR-137 in the osteogenic differentiation of human adipose-derived stem cells (hASCs) has not been reported. This study verified a general downward trend in miR-137 expression during the osteogenic differentiation of hASCs. MiR-137 knockdown promoted the osteogenesis of hASCs in vitro and in vivo. Mechanistically, inhibition of miR-137 activated the bone morphogenetic protein 2 (BMP2)-mothers against the decapentaplegic homolog 4 (SMAD4) pathway, whereas repressed lysine-specific histone demethylase 1 (LSD1), which was confirmed as a negative regulator of osteogenesis in our previous studies. Furthermore, LSD1 knockdown enhanced the expression of BMP2 and SMAD4, suggesting the coordination of LSD1 in the osteogenic regulation of miR-137. This study indicated that miR-137 negatively regulated the osteogenic differentiation of hASCs via the LSD1/BMP2/SMAD4 signaling network, revealing a new potential therapeutic target of hASC-based bone tissue engineering.     

Mechanisms involved in the regulation of histone lysine demethylases

Since the first histone lysine demethylase KDM1 (LSD1) was discovered in 2004, a great number of histone demethylases have been recognized and shown to play important roles in gene expression, as well as cellular differentiation and animal development. The chemical mechanisms and substrate specificities have already been extensively discussed elsewhere. This review focuses primarily on regulatory mechanisms that modulate demethylase recruitment and activity.